Axsome (reboxetine)

• 8-10 weeks

• Placebo controlled study

• 15-75 years of age

• Must have primary diagnosis of Narcolepsy Type 1 with Cataplexy

• History of >14 cataplexy attacks in 2-week period

• Optional open extension period with guaranteed study drug